CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
metformin hydrochloride +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01666730
NCT01666730Phase 2Completed

A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center·interventional·Posted Aug 16, 2012·Updated Aug 10, 2021

In Brief

A Phase 2 clinical trial evaluating metformin hydrochloride, oxaliplatin, and 3 other interventions for Acinar Cell Adenocarcinoma of the Pancreas and 3 related conditions. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

This phase II trial studies how well metformin hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin work in treating patients with metastatic pancreatic cancer. Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving metformin hydrochloride together with combination chemotherapy may kill more tumor cells

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 16, 2012
Enrollment StartFeb 21, 2013
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 13.9 years ago

Interventions

metformin hydrochloridedrug

Given PO

oxaliplatindrug

Given IV

leucovorin calciumdrug

Given IV

fluorouracildrug

Given IV

laboratory biomarker analysisother

Correlative studies